NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 10 மணி நேரத்திற்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Banka BioLoo Reports Q2 FY27 Standalone PAT of ₹41.57 Lakhs; ₹7.71 Cr Govt Dues Under Scrutiny
Banka BioLoo reported Q2 FY27 standalone revenue from operations of ₹16.52 crore, up 24.7% YoY from ₹13.25 crore in Q2 FY26. Standalone profit after tax turned positive to ₹41.57 lakhs compared to a loss of ₹110.38 lakhs in the year-ago period. For H1 FY27, revenue reached ₹32.47 crore with a net profit of ₹78.70 lakhs. The statutory auditor flagged an Emphasis of Matter regarding trade receivables and unbilled revenue of ₹770.74 lakhs (₹7.71 crore) due from government authorities in Andhra Pradesh, where recovery is backed by an interim High Court order without any provisioning.
உச்சம் நம்பிக்கை
என்ன மாறியதுBanka BioLoo published its Q2 and H1 FY27 financial results showing operational turnaround and profit recovery, alongside an auditor emphasis on pending state government receivables.
ஏன் இது முக்கியம்The company swung to profitability in Q2, but the ₹7.71 crore disputed receivables represent nearly 22% of its net worth (₹35 crore), posing significant balance sheet sensitivity.
Standalone Revenue (Q2 FY27): Rs. 1,651.59 lakhsStandalone PAT (Q2 FY27): Rs. 41.57 lakhsDisputed Govt Receivables: Rs. 770.74 lakhsReceivables vs Net Worth: ~22%
📅 குறுகிய காலம்Profit turnaround from losses in Q2 FY26 provides operational relief, though market attention will focus on the auditor's note on receivables.
📈 நீண்ட காலம்Sustained revenue growth in waste management solutions is essential to justify high valuation multiples, alongside resolving working capital lockups with municipal clients.
⚠ அபாய எச்சரிக்கைகள்
Unprovisioned government receivables of ₹770.74 lakhs subject to High Court interim orders
Working capital intensity with current trade receivables at ₹26.00 crore
👀 கவனிக்க வேண்டியவை
Monitor cash realization and court proceedings regarding the ₹7.71 crore government receivables, as well as margin sustainability in coming quarters.
Banka BioLoo Q2 FY27 Consolidated PAT at ₹13.11 Lakh vs Loss of ₹1.09 Cr YoY
Banka BioLoo reported consolidated revenue from operations of ₹11.76 cr for Q2 FY27 (ended September 30, 2026), down 9.6% YoY from ₹13.01 cr, but up 11.5% QoQ from ₹10.55 cr. The company turned profitable with a consolidated net profit of ₹13.11 lakh compared to a net loss of ₹1.09 cr in Q2 FY26. For H1 FY27, revenue stood at ₹22.31 cr with a PAT of ₹9.19 lakh compared to a loss of ₹1.09 cr in H1 FY26. Notably, auditor review drew attention to ₹7.71 cr in unprovided receivables from government bodies currently subject to ongoing dispute and High Court interim orders.
உச்சம் நம்பிக்கை
என்ன மாறியதுBanka BioLoo declared Q2 and H1 FY27 unaudited financial results, returning to marginal profitability after previous loss-making quarters.
ஏன் இது முக்கியம்While the business has returned to positive bottom line margins, revenue contracted year-on-year and a large portion of capital remains tied up in contested government receivables.
Consolidated Q2 Revenue: ₹1,176.22 லட்சம்Consolidated Q2 PAT: ₹13.11 லட்சம்Disputed Govt Receivables: ₹770.74 லட்சம்Govt Receivables vs Net Worth: ~22.7%
📅 குறுகிய காலம்Trading sentiment may remain tempered given the modest net profit level and continued auditor emphasis on uncollected government receivables.
📈 நீண்ட காலம்Turnaround sustainability depends on expanding private/commercial sanitation revenue and successfully recovering trapped working capital without write-offs.
⚠ அபாய எச்சரிக்கைகள்
Emphasis of Matter on ₹7.71 cr government receivables without provisioning
Low cash and cash equivalents of ₹3.70 lakh as of Sep 30, 2026
High working capital intensity in civil and sanitation contracts
👀 கவனிக்க வேண்டியவை
Monitor legal and recovery developments regarding the ₹7.71 cr receivables from municipal bodies, as this represents over 22% of the company's net worth (₹34 cr).
Banka BioLoo Outlines ₹107 Cr Order Book and Megaliter Platform in AGM Presentation
Banka BioLoo shared its FY26 AGM presentation detailing its business model and financial turnaround. For FY26, total income stood at ₹58.39 crore (+7.1% YoY) with consolidated EBITDA turning positive to ₹6.49 crore and PAT reaching ₹0.39 crore. The company highlighted an unexecuted order book of ₹107 crore (nearly 1.9x FY26 revenue), with ₹70 crore targeted for execution over the next 12 months. Additionally, its asset-holding arm Megaliter reports a lifetime value (LTV) portfolio of over ₹122 crore across 16 contracted projects.
உச்சம் நம்பிக்கை
என்ன மாறியதுBanka BioLoo published its FY26 AGM investor deck providing granular transparency into its Megaliter co-model, order book visibility, and cash conversion metrics.
ஏன் இது முக்கியம்While the order book is robust at ~1.9x annual revenue, FY26 cash generation was constrained by working capital lockups in receivables and contract assets.
Total unexecuted order book: ₹107 கோடிOrder book vs TTM revenue: ~191%Next 12M executable orders: ₹70 கோடிFY26 Consolidated PAT: ₹0.39 கோடிMegaliter Portfolio LTV: ₹122+ crs
📅 குறுகிய காலம்Informational presentation; unlikely to move markets significantly in the near term as FY26 numbers were already reported.
📈 நீண்ட காலம்Crucial for assessing transition to a recurring-revenue sanitation and water-services model, dependent on successful project commissioning and cash collection.
⚠ அபாய எச்சரிக்கைகள்
High working capital absorption (₹6.10 crore absorbed in FY26)
Significant trade receivables (₹29.15 crore against ₹58.39 crore revenue)
Execution and commissioning delays on WIP assets
👀 கவனிக்க வேண்டியவை
Track the quarterly conversion rate of the ₹70 crore 12-month order pipeline into revenue and monitor receivable collections to ensure operating cash flows improve.
Banka BioLoo Q1 PAT up 162% to ₹0.37 Cr; Unexecuted Order Book reaches ₹82 Cr
Banka BioLoo reported a 20.5% YoY revenue growth to ₹16.40 Cr for Q1 FY26-27, with PAT rising 162% to ₹0.37 Cr. The company maintains a strong unexecuted order book of ₹82 Cr, which is approximately 144% of its TTM revenue, providing multi-quarter visibility. Its subsidiary, Megaliter Varunaa, has scaled to a ₹122 Cr Lifetime Value (LTV) across 15 projects, focusing on long-term water infrastructure. Despite the growth, the company remains a micro-cap with thin margins and a high P/E ratio.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has demonstrated a strong recovery in profitability and order book growth compared to the losses seen in FY25.
ஏன் இது முக்கியம்The significant order book relative to the company's market cap and revenue suggests potential for a re-rating if execution remains consistent and margins improve.
Q1 வருவாய்: ₹16.40 கோடிUnexecuted Order Book: ₹82 கோடிOrder Book vs TTM Revenue: 143.8%Megaliter Net LTV: ₹122 கோடிQ1 PAT: ₹0.37 கோடி
📅 குறுகிய காலம்The stock may see positive momentum due to the sharp YoY growth in PAT and the substantial unexecuted order book visibility.
📈 நீண்ட காலம்The structural shift toward long-term O&M and BOOT contracts in water infrastructure could provide more stable, recurring revenue over 7-10 year cycles.
⚠ அபாய எச்சரிக்கைகள்
High P/E ratio of 248.4
Thin net profit margins
High dependence on government and railway contracts
👀 கவனிக்க வேண்டியவை
Monitor the execution pace of the ₹82 Cr order book and the margin trajectory of the Megaliter Varunaa projects as they transition from early-stage to steady-state revenue recognition.
Banka BioLoo Q1 Revenue Falls 13% to ₹10.71 Cr; ₹7.39 Cr Govt Receivables Under Dispute
Banka BioLoo reported a weak Q1 FY27 with consolidated revenue declining 13.1% YoY to ₹10.71 Cr. The company swung to a marginal net loss of ₹0.04 Cr, compared to a break-even position in the same quarter last year. A significant concern for investors is the ₹7.39 Cr in trade receivables from government bodies like Swachha Andhra Corporation, which are currently under dispute but supported by an interim High Court order. The board also approved the re-appointment of the Managing Director and granted 16,000 ESOPs at face value.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported a 13% YoY revenue decline and a shift to a net loss for Q1 FY27, while highlighting ₹7.39 Cr in disputed government receivables.
ஏன் இது முக்கியம்For a micro-cap with a ₹99 Cr market cap, the inability to collect 13% of its annual revenue from government clients strains cash flows and limits growth capital.
📅 குறுகிய காலம்Expect negative sentiment due to the earnings miss and the persistent uncertainty regarding the recovery of government dues.
📈 நீண்ட காலம்Long-term stability depends on resolving the receivable dispute and diversifying the client base away from high-risk government contracts.
⚠ அபாய எச்சரிக்கைகள்
Significant government receivables under dispute (₹7.39 Cr)
Revenue contraction of 13% YoY
High P/E valuation of 248x relative to current earnings
👀 கவனிக்க வேண்டியவை
Monitor the recovery of the ₹7.39 Cr government receivables and the impact of the new Labour Code on gratuity liabilities in upcoming quarters.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Banka BioLoo Reports Q1 FY27 Net Loss of ‹0.14 Cr; Revenue Drops 39% QoQ
Banka BioLoo Limited reported a consolidated net loss of ‹0.14 crore for Q1 FY27, a sharp reversal from the ‹1.60 crore profit in the preceding quarter. Revenue for the quarter stood at ‹10.71 crore, representing a 39% decline sequentially and a 13% drop year-on-year. A significant concern remains ‹7.38 crore in trade receivables from government bodies, which are currently under internal and legal review. The board also approved the grant of 16,000 ESOPs at a face value of ‹10 and the re-appointment of the Managing Director.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company transitioned from a profitable quarter to a loss-making one, accompanied by a significant sequential revenue contraction.
ஏன் இது முக்கியம்The sharp drop in revenue and the swing to a loss, combined with high P/E valuation (248x), suggests immediate pressure on the stock price and highlights risks in government-linked project execution.
Q1 FY27 Revenue: ‹10.71 crQ1 FY27 Net Loss: ‹0.14 crGovernment Receivables: ‹7.38 crReceivables vs TTM Revenue: ~13%ESOP Exercise Price: ‹10.00
📅 குறுகிய காலம்The stock may face downward pressure due to the weak quarterly performance and the shift back into losses.
📈 நீண்ட காலம்Long-term sustainability depends on resolving receivable disputes and scaling the waste management business beyond government tenders.
⚠ அபாய எச்சரிக்கைகள்
Significant trade receivables (‹7.38 cr) from government bodies under review
High revenue volatility
Swing to net loss
👀 கவனிக்க வேண்டியவை
Investors should monitor the recovery status of the ‹7.38 crore government receivables and observe if the company can stabilize its operating margins, which have been volatile.
Banka BioLoo Q1 FY27: Revenue Declines 12% YoY to Rs 10.71 Cr; Swings to Net Loss
Banka BioLoo reported a weak set of numbers for Q1 FY27, with consolidated revenue falling 12.3% YoY to Rs 10.71 Cr. The company swung to a consolidated net loss of Rs 3.93 Lakhs, a sharp decline from the Rs 1.60 Cr profit recorded in the preceding quarter (March 2026). A significant concern remains the Rs 7.38 Cr in trade receivables from government bodies, which is currently under discussion and represents approximately 21.7% of the company's net worth. The board also approved the re-appointment of Namita Sanjay Banka as Managing Director and granted 16,000 new ESOPs.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from a profitable Q4 FY26 to a loss-making Q1 FY27, alongside a double-digit year-on-year revenue decline.
ஏன் இது முக்கியம்For a micro-cap company with a Rs 99 Cr market cap, the combination of falling revenue and high government receivables (21.7% of net worth) creates significant working capital and valuation pressure.
Q1 FY27 Revenue: Rs 10.71 கோடிQ1 FY27 Net Loss: Rs 3.93 LakhsYoY Revenue Growth: -12.3%QoQ Revenue Growth: -39.8%Govt Receivables vs Net Worth: 21.7%
📅 குறுகிய காலம்The stock may face downward pressure in the short term due to the earnings miss and the swing from profit to loss.
📈 நீண்ட காலம்Long-term sustainability depends on the company's ability to scale its waste management solutions and resolve persistent payment delays from government contracts.
⚠ அபாய எச்சரிக்கைகள்
High government receivables concentration
Significant sequential revenue volatility
Micro-cap liquidity risk
👀 கவனிக்க வேண்டியவை
Investors should monitor the recovery of the Rs 7.38 Cr government receivables and the company's ability to stabilize its top-line, which saw a nearly 40% sequential drop from the March 2026 quarter.
Banka BioLoo Limited has successfully completed the redemption of 430 secured, unrated, and unlisted non-convertible debentures (NCDs). The total repayment amount stands at Rs 4.30 crore, with each unit valued at Rs 1,00,000. The company received a No Due Certificate on June 25, 2026, confirming that the facility was fully repaid on June 22, 2026. This debt reduction is expected to lower interest costs and improve the company's overall financial health.
முக்கிய அம்சங்கள்
Redeemed 430 secured, unrated, and unlisted NCDs at par value.Total aggregate value of the redemption is Rs 4.30 crore.Full repayment confirmed by the Debenture Holder as of June 22, 2026.Received official No Due Certificate dated June 24, 2026, confirming zero outstanding debt for this facility.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive sign of financial discipline and deleveraging. Monitor the company's upcoming quarterly results for improvements in net profit margins due to reduced interest outgo.
Banka BioLoo Reports FY26 Turnaround with ₹38.21 Lakh Profit vs ₹929.64 Lakh Loss in FY25
Banka BioLoo Limited has reported a significant financial turnaround for the fiscal year ended March 31, 2026, posting a net profit of ₹38.21 lakhs compared to a substantial loss of ₹929.64 lakhs in the previous year. Revenue from operations grew by 8.6% year-on-year to reach ₹5,975.76 lakhs. The fourth quarter was particularly strong, contributing ₹157.06 lakhs to the bottom line. However, investors should note an auditor's emphasis on ₹687.44 lakhs in trade receivables from government bodies, of which ₹125.26 lakhs have been outstanding for over two years without provision.
முக்கிய அம்சங்கள்
Revenue from operations increased to ₹5,975.76 lakhs in FY26 from ₹5,500.03 lakhs in FY25Achieved a net profit of ₹38.21 lakhs in FY26, recovering from a net loss of ₹929.64 lakhs in FY25Q4 FY26 standalone profit stood at ₹157.06 lakhs compared to a loss of ₹172.90 lakhs in Q4 FY25Earnings Per Share (EPS) improved to ₹0.35 from a negative ₹8.57 in the previous fiscal yearAuditors highlighted ₹687.44 lakhs in government receivables, with ₹125.26 lakhs overdue for more than two years
👀 கவனிக்க வேண்டியவை
The company has successfully moved from losses to profitability, which is a positive sign for recovery. Investors should monitor the collection of long-pending government receivables as any future provisioning could impact the bottom line.
Banka BioLoo Limited has approved its audited standalone and consolidated financial results for the quarter and full year ending March 31, 2026. The statutory auditors, B. D. Saboo & Associates, issued an unmodified opinion, indicating that the financial statements present a true and fair view. The company also announced the appointment of a new Company Secretary and Internal Auditors for the 2026-2027 fiscal year. These administrative updates and the clean audit report demonstrate the company's commitment to regulatory compliance and corporate governance.
முக்கிய அம்சங்கள்
Approved audited standalone and consolidated financial results for the year ended March 31, 2026.Statutory auditors issued an unmodified/unqualified opinion on the financial results.Appointed Ms. Srilakshmi Manjula Chaitanya Chunduru as Company Secretary and Compliance Officer.Appointed M/s. SMAB & Associates as Internal Auditors for the financial year 2026-2027.Updated and adopted amended policies for Whistle blower/Vigil mechanism and materiality disclosures.
👀 கவனிக்க வேண்டியவை
Investors should review the detailed financial tables on the company's website to assess specific growth and margin trends for FY26. The unmodified audit opinion provides confidence in the reported figures.
Banka BioLoo Q4 FY26 Turnaround: Revenue Up 29% YoY, PAT Positive at ₹1.57 Cr
Banka BioLoo reported a significant financial turnaround in Q4 FY26, with standalone revenue growing 29% YoY to ₹18.13 crore. The company moved from a net loss to a PAT of ₹1.57 crore for the quarter and achieved full-year profitability with a PAT of ₹38.2 lakh. The order book remains healthy at ₹107 crore, split between Railways (₹38 crore) and WaSH (₹69 crore) segments. Management highlighted geographic expansion into Mumbai and Bangalore and a shift towards higher-margin WaSH execution.
முக்கிய அம்சங்கள்
Standalone Q4 revenue grew 29% YoY to ₹18.13 crore, while full-year revenue rose 10% to ₹61.01 crore.Achieved a major turnaround with FY26 PAT of ₹38.2 lakh compared to a loss of ₹9.3 crore in FY25.Total unexecuted order book stands at ₹107 crore, providing strong revenue visibility for the next fiscal year.WaSH segment order booking for the year reached ₹56 crore, with new project wins from Grade-A developers like Reliance and Brigade.EBITDA for Q4 FY26 turned positive at ₹2.54 crore versus a loss of ₹0.67 crore in the previous year's quarter.
👀 கவனிக்க வேண்டியவை
The company has successfully pivoted back to profitability after a difficult FY25, making it a recovery play in the sanitation and water treatment space. Investors should monitor the execution of the ₹107 crore order book and margin sustainability in the expanding WaSH segment.
Banka BioLoo to Provide Rs 10 Crore Corporate Guarantee for Subsidiary Megaliter Varunaa
Banka BioLoo Limited has approved the issuance of a corporate guarantee to secure credit facilities for its subsidiary, Megaliter Varunaa Private Limited. The guarantee covers an amount up to Rs 10 Crores in favor of Northern Arc Capital Limited. This commitment is unconditional and irrevocable, lasting until the subsidiary fully discharges its debt obligations. While it creates a contingent liability on a standalone basis, the company notes there is no impact on consolidated financials.
முக்கிய அம்சங்கள்
Corporate guarantee issued for subsidiary Megaliter Varunaa Private Limited for up to Rs 10 CroresCredit facility to be provided by lender Northern Arc Capital Limited in one or more tranchesGuarantee is unconditional and irrevocable, covering principal, interest, and other chargesTransaction is at arm's length, though the parent company is a promoter of the borrowerThe guarantee will be recorded as a contingent liability on the standalone balance sheet
👀 கவனிக்க வேண்டியவை
Investors should monitor the subsidiary's ability to service its debt, as a default would impact the parent company's standalone financials. No immediate action is necessary as this is a standard corporate support mechanism.
Banka BioLoo Q3 FY26: Revenue Up 15% YoY, EBITDA Turns Positive at ₹90 Lakhs
Banka BioLoo reported a 15% YoY growth in standalone gross sales revenue to ₹18.78 crore for Q3 FY26. The company achieved a significant operational turnaround with standalone EBITDA rising to ₹90 lakh from a loss of ₹33.6 lakh in the previous year, driven by cost optimization and increased execution in the WaSH segment. While the company still reported a consolidated net loss of ₹12.45 lakh, it is a substantial improvement from the ₹145.54 lakh loss in Q3 FY25. The total unexecuted order book remains robust at ₹113 crore, providing strong revenue visibility.
முக்கிய அம்சங்கள்
Standalone Gross Sales Revenue increased by 15% YoY to ₹18.78 crore in Q3 FY26.Standalone EBITDA turned positive at ₹90 lakh, reflecting a ~373% increase from the previous year's loss.Total unexecuted order book stands at ₹113 crore, split between Railways (₹49.5 cr) and WaSH (₹63.5 cr).New order wins in the WaSH segment totaled ₹14.64 crore during Q3, including expansion into Mumbai and Bangalore.Consolidated net loss narrowed significantly to ₹12.45 lakh from ₹145.54 lakh in the same quarter last year.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to maintain EBITDA margins as it executes its ₹113 crore order book. The shift towards the WaSH segment and expansion into new geographies like Mumbai and Bangalore are positive indicators for long-term growth.
Banka BioLoo Q3 FY26: Revenue Grows to ₹15.93 Cr, Net Loss Narrows Significantly to ₹0.22 Cr
Banka BioLoo reported a revenue of ₹15.93 crore for Q3 FY26, up from ₹14.19 crore in the same quarter last year. The company significantly narrowed its net loss to ₹0.22 crore from a loss of ₹1.46 crore YoY, indicating improved operational efficiency. Total expenses for the quarter stood at ₹16.22 crore, with material costs being the largest component at ₹5.71 crore. While the company remains loss-making on a nine-month basis with a loss of ₹1.19 crore, the quarterly trend shows a strong recovery toward break-even.
முக்கிய அம்சங்கள்
Revenue from operations increased by 12.3% YoY to ₹15.93 crore from ₹14.19 croreQuarterly net loss narrowed by 85% YoY to ₹0.22 crore compared to ₹1.46 croreNine-month total income reached ₹42.88 crore, showing steady growth over the previous yearEarnings Per Share (EPS) improved to (0.20) for the quarter, up from (1.35) in Q3 FY25Finance costs for the quarter were ₹0.66 crore, showing a slight decrease from ₹0.72 crore YoY
👀 கவனிக்க வேண்டியவை
The narrowing of losses and steady revenue growth are encouraging signs of a potential turnaround. Investors should monitor the company's ability to achieve net profitability in the upcoming quarters before increasing exposure.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
